Kymera Therapeutics Inc (KYMR) balance sheet and financial health

NASDAQ · Health Care

$121.52 -3.44% Close Nov 17, 2026 Live

TrendArc score 39 of 100 · Health 1.1 · Momentum 7.2 · Moat 4.5 · scored Nov 17, 2026 · How the score works

Cash and short-term investments less borrowings, December 31, 2025

$853 million more cash than borrowings

Kymera Therapeutics held $854 million of cash and short-term investments against $1 million of borrowings on December 31, 2025. Its lease liabilities, shown apart from borrowings, were $82 million.

Borrowings to equity

0.00

$1.46M of borrowings on $1.58B of equity, Dec 2025

Return on invested capital

-31.5%

latest quarter to September 2026, annualised; the stock card's measure

Cash and borrowings at each fiscal year end

$250M$500M$750M$1.00B20182019202020212022202320242025Cash and short-terminvestments $854MBorrowings $1.46M$250M$500M$750M$1.00B2019202120232025Cash and short-term investments $854MBorrowings $1.46M

What the balance sheet holdsDecember 31, 2025

Assets $1.74BCash and short-term investments$854MOther current assets$17.1MLong-term investments$771MProperty, goodwill and other$100MFunded by $1.74BBorrowings$1.46MOther liabilities$79.4MShareholders' equity$1.58BSmaller items: lease liabilities $82.3MAssets $1.74BCash and short-term investments$854MOther current assets$17.1MLong-term investments$771MProperty, goodwill and other$100MFunded by $1.74BBorrowings$1.46MLease liabilities$82.3MOther liabilities$79.4MShareholders' equity$1.58B

"Other liabilities" is total liabilities less borrowings and lease liabilities; "Property, goodwill and other" is total assets less the current assets and long-term investments.

Balance sheet, the last 8 fiscal year ends

In billions of US dollars, at each fiscal year end, named by the month it ended. Borrowings are bonds, notes, loans and commercial paper; lease liabilities, operating and finance, are shown apart.
Fiscal year endDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Assets
Cash and short-term investments0.850.490.380.410.450.30——
Receivables0.000.000.010.000.000.00——
Inventory0.000.000.000.000.000.00——
Other current assets0.020.020.010.010.000.00——
Total current assets0.870.510.410.420.450.30——
Long-term investments0.770.360.060.150.130.16——
Total assets1.740.980.580.600.610.49——
Liabilities and equity
Current liabilities0.080.070.090.070.090.11——
Borrowings0.000.00———0.00——
Lease liabilities0.080.09———0.02——
Total liabilities0.160.140.180.110.150.20——
Shareholders' equity1.580.840.390.490.460.28——
Financial health
Cash less borrowings0.850.49———0.30——
Borrowings to equity0.000.00———0.00——

A dash in a whole column: that year's assets did not equal its liabilities, equity and minority interests in our data, so it is left out.

Interest cover is operating income over interest expense, for full fiscal years. Minority interests and other is total assets less total liabilities and shareholders' equity (calculated by TrendArc). Company filings as standardised by Tiingo; borrowings and lease liabilities told apart with the lines the company files on SEC EDGAR, and a dash where the two cannot be told apart. Rebuilt nightly.

Kymera Therapeutics against its peers

CompanyCash less borrowingsBorrowings to equityInterest coverReturn on invested capital
Kymera TherapeuticsKYMR +$853M 0.00 — -31.5%
Madrigal PharmaceuticalsMDGL +$619M 0.55 — 22.6%
Ensign GroupENSG +$193M 0.08 53.2x 8.8%
Tg TherapeuticsTGTX -$240M 1.30 4.6x 16.8%
InsuletPODD -$353M 0.59 8.0x 22.4%
Henry ScheinHSIC -$2.94B 0.96 4.4x 8.2%
Universal Health ServicesUHS -$5.54B 0.75 12.8x 9.1%
DaVitaDVA -$10.1B — 3.5x 7.3%

Each company's newest balance sheet; borrowings leave lease liabilities out; interest cover for its newest fiscal year; return on invested capital is the stock card's measure. A dash where a measure does not apply.

Next

Follow Kymera Therapeutics with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Kymera Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.